NCT06476275View on ClinicalTrials.gov

Single Dose Texas 2017 (H3N2) Challenge Study

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

February 10, 2025

Conditions
Influenza Viral Infections
Interventions
BIOLOGICAL

Influenza A/Texas/71/2017 (H3N2)

Virus will be administered intranasally

BIOLOGICAL

Sham placebo

Placebo will be administered intranasally

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Owlstone Ltd

INDUSTRY

collaborator

Darwin Biosciences

UNKNOWN

lead

Duke University

OTHER

NCT06476275 - Single Dose Texas 2017 (H3N2) Challenge Study | Biotech Hunter | Biotech Hunter